Q32 Bio Management
Management criteria checks 1/4
Q32 Bio's CEO is Jodie Morrison, appointed in Mar 2024, has a tenure of 1.67 years. total yearly compensation is $6.00M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $48.61K. The average tenure of the management team and the board of directors is 2.1 years and 1.7 years respectively.
Key information
Jodie Morrison
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 10.45% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.1yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$42m |
| Jun 30 2025 | n/a | n/a | -US$52m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$6m | US$627k | -US$48m |
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$57m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$1m | US$525k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | US$2m | US$120k | -US$43m |
Compensation vs Market: Jodie's total compensation ($USD6.00M) is above average for companies of similar size in the US market ($USD598.08K).
Compensation vs Earnings: Jodie's compensation has increased whilst the company is unprofitable.
CEO
Jodie Morrison (49 yo)
Ms. Jodie Pope Morrison was Independent Director of Verve Therapeutics, Inc. from June 2024 to July 25, 2025. Ms. Jodie Pope Morrison serves as Chief Executive Officer and Director of Q32 Bio Inc. since Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$6.00m | 0.18% $ 48.6k | |
| CFO & President | 1.8yrs | US$2.85m | 0.074% $ 19.6k | |
| Co-founder | 8.2yrs | US$716.22k | 0.55% $ 143.7k | |
| Chief Technology Officer | 2.1yrs | no data | no data | |
| Senior VP & Head of People | 3.2yrs | no data | no data | |
| Executive Vice President of Corporate Strategy & Program Operations | 2.8yrs | no data | no data | |
| Interim Chief Medical Officer | less than a year | no data | no data |
Experienced Management: QTTB's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$6.00m | 0.18% $ 48.6k | |
| Independent Director | 1.7yrs | US$223.66k | 0.045% $ 11.7k | |
| Independent Director | 1.7yrs | US$222.63k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.7yrs | US$199.10k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$199.87k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$414.53k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$217.53k | 0.0098% $ 2.6k | |
| Independent Director | 1.7yrs | US$199.10k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | 3.8yrs | no data | no data |
Experienced Board: QTTB's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/16 08:54 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Q32 Bio Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Smith | Leerink Partners LLC |
| Jay Olson | Oppenheimer & Co. Inc. |
| Christopher Raymond | Piper Sandler Companies |